Evidence map›Paper›PMID 34424299›Full record

ArticleDisease models & mechanisms2021

Identification of fibronectin 1 as a candidate genetic modifier in a Col4a1 mutant mouse model of Gould syndrome.

Mao Mao, Tanav Popli, Marion Jeanne, Kendall Hoff, Saunak Sen, Douglas B Gould

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Vascular contribution to cognitive impairment and dementia (VCID): proceedings of 2025 workshop of the Jackson Laboratory.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  2. Basement membrane structure and function: Relating biology to mechanics.Matrix biology : journal of the International Society for Matrix Biology · 2025
    Review
  3. Collagen IV in Gould syndrome and Alport syndrome.Nature reviews. Nephrology · 2025
    Review
  4. Review
  5. Article
  6. Multimodal neuroimaging ofFrontiers in neuroscience · 2025
    Article
  7. Skeletal pathology in mouse models of Gould syndrome is partially alleviated by genetically reducing TGFβ signaling.Matrix biology : journal of the International Society for Matrix Biology · 2024
    Article
  8. Article
  9. Article
  10. PI3K block restores age-dependent neurovascular coupling defects associated with cerebral small vessel disease.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  11. Article
  12. Elevated TGFβ signaling contributes to cerebral small vessel disease in mouse models of Gould syndrome.Matrix biology : journal of the International Society for Matrix Biology · 2023
    Article
  13. Elevated TGFβ signaling contributes to ocular anterior segment dysgenesis in Col4a1 mutant mice.Matrix biology : journal of the International Society for Matrix Biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mao MaoDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-7026-5790
Tanav PopliDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.
Marion JeanneDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.
Kendall HoffDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-5226-6682
Saunak SenDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-4519-6361
Douglas B GouldDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-5127-5328
University of California, San Francisco · USUniversity of Tennessee Health Science Center · US

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAMBA, DEEPAK ASHOK · 1985 to 2024
$16.8M
Genetically testing mechanisms of ocular development and diseaseR01EY019887 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Douglas Gould · 2010 to 2026
$5.5M
Genetic and Mechanistic Study of Cerebral Small Vessel DiseaseR01NS096173 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOULD, DOUGLAS · 2017 to 2021
$3.5M
NEI NIH HHS P30 EY002162NEI NIH HHS R01 EY019887NINDS NIH HHS R01 NS096173
6 · The paper itself

Abstract

Collagen type IV alpha 1 and alpha 2 (COL4A1 and COL4A2) are major components of almost all basement membranes. COL4A1 and COL4A2 mutations cause a multisystem disorder that can affect any organ but typically involves the cerebral vasculature, eyes, kidneys and skeletal muscles. In recent years, patient advocacy and family support groups have united under the name of Gould syndrome. The manifestations of Gould syndrome are highly variable, and animal studies suggest that allelic heterogeneity and genetic context contribute to the clinical variability. We previously characterized a mouse model of Gould syndrome caused by a Col4a1 mutation in which the severities of ocular anterior segment dysgenesis (ASD), myopathy and intracerebral hemorrhage (ICH) were dependent on genetic background. Here, we performed a genetic modifier screen to provide insight into the mechanisms contributing to Gould syndrome pathogenesis and identified a single locus [modifier of Gould syndrome 1 (MoGS1)] on Chromosome 1 that suppressed ASD. A separate screen showed that the same locus ameliorated myopathy. Interestingly, MoGS1 had no effect on ICH, suggesting that this phenotype could be mechanistically distinct. We refined the MoGS1 locus to a 4.3 Mb interval containing 18 protein-coding genes, including Fn1, which encodes the extracellular matrix component fibronectin 1. Molecular analysis showed that the MoGS1 locus increased Fn1 expression, raising the possibility that suppression is achieved through a compensatory extracellular mechanism. Furthermore, we found evidence of increased integrin-linked kinase levels and focal adhesion kinase phosphorylation in Col4a1 mutant mice that is partially restored by the MoGS1 locus, implicating the involvement of integrin signaling. Taken together, our results suggest that tissue-specific mechanistic heterogeneity contributes to the variable expressivity of Gould syndrome and that perturbations in integrin signaling may play a role in ocular and muscular manifestations.

Indexed as

Genes, ModifierAbnormalities, MultipleAnimalsCerebral HemorrhageChromosome MappingChromosomes, MammalianCollagen Type IVEye AbnormalitiesFibronectinsGenes, SuppressorGenetic LociIntegrinsMiceMice, Mutant StrainsMuscular DiseasesPorencephalyCol4a1 protein, mouseCollagen Type IVFibronectinsIntegrinsBasement membraneCOL4A1FibronectinGould syndromeIntegrin signalingModifier

Identifiers

PMID34424299
PMCPMC8106953
OpenAlexW3134117031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.